Exploring CD79b, LC3, and TERT expression in NON-GCB DLBCL: markers associated with Rituximab-Cyclophosphamide-Doxorubicin-Vincristin-Prednisone treatment response
Blood Research · 2026-12 · 61 (1)
DOI: 10.1007/s44313-026-00129-2 ↗Kurz gefasst
Fachartikel in der Zeitschrift Blood Research, online erschienen am 11.05.2026. Verfasst von Bethy S Hernowo und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Anatomical Pathology, Faculty of Medicine, Padjadjaran University/Dr. Hasan Sadikin General Hospital, Bandung, West Java, Indonesia. be…. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 23 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Academic Leadership Grant.
Abstract (Originalsprache)
Introduction
Diffuse large B-cell lymphoma (DLBCL) represents the most common subtype of non-Hodgkin lymphoma. The non-germinal center B-cell-like (non-GCB) subtype is associated with a poor prognosis and reduced response rates to rituximab cyclophosphamide-doxorubicin-vincristin-prednisone (R-CHOP) therapy. Resistance may involve cluster of differentiation 79B (CD79B)-driven B-cell receptor (BCR)/nuclear factor kappa B activation, microtubule-associated protein 1 light chain 3 (LC3)-mediated autophagy, and telomerase reverse transcriptase (TERT)-related survival signaling. The interrelationships between these markers and their associations with therapeutic responses remain unclear. This study evaluated the association between CD79B, LC3, and TERT expression and response to R-CHOP in non-GCB DLBCL.
Methods
This analytical case–control study included 58 paraffin-embedded samples from patients with non-GCB DLBCL diagnosed at the Dr. Hasan Sadikin General Hospital, Bandung, Indonesia (2017–2023). Tumor characteristics were assessed using immunohistochemical staining for CD79B, LC3, and TERT. Expression levels were evaluated semi-quantitatively based on staining intensity and the proportion of positive tumor cells. Treatment responses were categorized as response (complete/partial) or non-response (stable/progressive). Statistical analyses were performed using the chi-square test, Fisher’s exact test, and binary logistic regression, with significance defined as p < 0.05.
Results
TERT, CD79B, and LC3 expression was detected in 53.4%, 55.2%, and 62.1% of the cases, respectively. Among non-responsive patients, TERT and LC3 expression rates were 62.1% and 69.0% ( p > 0.05), respectively. CD79B expression was significantly associated with non-response ( p = 0.002). Moreover, multivariate analysis identified positive CD79B expression as an independent predictor of non-response to R-CHOP therapy (OR = 9.72).
Conclusion
CD79B expression was independently associated with a poor response to R-CHOP therapy in non-GCB DLBCL. The positive association between TERT and LC3 suggests the presence of additional metabolic adaptation mechanisms supporting tumor survival.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Anatomical Pathology, Faculty of Medicine, Padjadjaran University/Dr. Hasan Sadikin General Hospital, Bandung, West Java, Indonesia. bethy.suryawathy@unpad.ac.id.
- Department of Anatomical Pathology, Faculty of Medicine, Padjadjaran University/Dr. Hasan Sadikin General Hospital, Bandung, West Java, Indonesia.
- Department of Internal Medicine, Faculty of Medicine, Padjadjaran University/Dr. Hasan Sadikin General Hospital, Bandung, West Java, Indonesia.
- School of Economics and Business, Telkom University, Bandung, West Java, Indonesia.
Förderung
- Academic Leadership Grant
Zitieren
APA
Hernowo, B. S., Ilanur, A., Agustina, H., Oehadian, A., Dewayani, B. M., Yantisetiasti, A., Usman, H. A., Primastari, E., Husain, O., Nuraeni, N., & Trianasari, N. (2026). Exploring CD79b, LC3, and TERT expression in NON-GCB DLBCL: markers associated with Rituximab-Cyclophosphamide-Doxorubicin-Vincristin-Prednisone treatment response. Blood Research, 61(1). https://doi.org/10.1007/s44313-026-00129-2
Vancouver
Hernowo BS, Ilanur A, Agustina H, Oehadian A, Dewayani BM, Yantisetiasti A, et al. Exploring CD79b, LC3, and TERT expression in NON-GCB DLBCL: markers associated with Rituximab-Cyclophosphamide-Doxorubicin-Vincristin-Prednisone treatment response. Blood Research. 2026;61(1). doi:10.1007/s44313-026-00129-2
BibTeX
@article{Hernowo2026,
author = {Hernowo, Bethy S and Ilanur, Arnita and Agustina, Hasrayati and Oehadian, Amaylia and Dewayani, Birgitta M and Yantisetiasti, Anglita and Usman, Hermin A and Primastari, Etis and Husain, Okky and Nuraeni, Nia and Trianasari, Nurvita},
title = {Exploring CD79b, LC3, and TERT expression in NON-GCB DLBCL: markers associated with Rituximab-Cyclophosphamide-Doxorubicin-Vincristin-Prednisone treatment response},
journal = {Blood Research},
year = {2026},
volume = {61},
number = {1},
doi = {10.1007/s44313-026-00129-2}
}
EUVIMED